Vivesto AB (OASMY)
OASMY Stock Price Chart
Explore Vivesto AB interactive price chart. Choose custom timeframes to analyze OASMY price movements and trends.
OASMY Company Profile
Discover essential business fundamentals and corporate details for Vivesto AB (OASMY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
23 Oct 2015
Employees
4.00
Website
https://www.vivesto.comCEO
Erik Kinnman Assoc. Prof.,
Description
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
OASMY Financial Timeline
Browse a chronological timeline of Vivesto AB corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 12 Nov 2025
Earnings released on 20 Aug 2025
Earnings released on 8 May 2025
EPS came in at -$0.02 .
Earnings released on 20 Feb 2025
EPS came in at -$0.02 .
Earnings released on 14 Nov 2024
EPS came in at -$0.02 .
Earnings released on 22 Aug 2024
EPS came in at -$0.01 .
Earnings released on 23 May 2024
EPS came in at -$0.01 .
Earnings released on 22 Feb 2024
EPS came in at -$0.12 , while revenue for the quarter reached $6.61M .
Earnings released on 30 Sept 2023
EPS came in at -$0.02 , while revenue for the quarter reached $77.00K .
Earnings released on 30 Jun 2023
EPS came in at -$0.16 .
Earnings released on 31 Mar 2023
EPS came in at -$0.11 .
Earnings released on 31 Dec 2022
EPS came in at -$1.29 .
Earnings released on 30 Sept 2022
EPS came in at -$0.42 , while revenue for the quarter reached $1.02M .
Earnings released on 30 Jun 2022
EPS came in at -$0.23 .
Earnings released on 31 Mar 2022
EPS came in at -$0.16 .
Dividend declared on 22 Mar 2022
A dividend of $0.00 per share was announced, adjusted to $0.00. The dividend was paid on 4 Apr 2022.
Earnings released on 31 Dec 2021
EPS came in at -$0.02 , while revenue for the quarter reached $9.64M , beating expectations by +42.35K%.
Earnings released on 18 Nov 2021
EPS came in at -$0.21 , while revenue for the quarter reached $11.92M , beating expectations by +52.39K%.
Earnings released on 19 Aug 2021
EPS came in at -$0.35 , while revenue for the quarter reached $4.60M , beating expectations by +18.94K%.
Earnings released on 27 May 2021
EPS came in at -$0.27 , while revenue for the quarter reached $37.00K , missing expectations by -78.14%.
Earnings released on 9 Dec 2020
EPS came in at -$0.04 , while revenue for the quarter reached -$200.16M .
Earnings released on 9 Sept 2020
EPS came in at -$0.04 , while revenue for the quarter reached $154.00K .
OASMY Stock Performance
Access detailed OASMY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.